Maternal serum second trimester screening for chromosomal disorders and neural tube defects in a government hospital of North India

2012 ◽  
Vol 32 (12) ◽  
pp. 1192-1196 ◽  
Author(s):  
Gurjit Kaur ◽  
Jyoti Srivastav ◽  
Avneet Kaur ◽  
Anju Huria ◽  
Poonam Goel ◽  
...  
Keyword(s):  
Neural Tube ◽  
Neural Tube Defects ◽  
Maternal Serum ◽  
North India ◽  
Second Trimester ◽  
Government Hospital ◽  
Chromosomal Disorders ◽  
Second Trimester Screening ◽  
Trimester Screening

scholarly journals The Effect of Down Syndrome Biochemical Markers on Predicting Severity of Preeclampsia

2020 ◽  
Author(s):  
AYSE OZBAN
Keyword(s):  
Down Syndrome ◽  
Pregnant Women ◽  
Biochemical Markers ◽  
First Trimester ◽  
Maternal Serum ◽  
Screening Tests ◽  
Second Trimester ◽  
Study Results ◽  
Second Trimester Screening ◽  
Trimester Screening

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.

Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A

1996 ◽  
Vol 44 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Euan M. Wallace ◽  
Ian A. Swanston ◽  
Alan S. McNeilly ◽  
J. Peter Ashby ◽  
Gillian Blundell ◽  
...  
Keyword(s):  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Inhibin A ◽  
Second Trimester Screening ◽  
Trimester Screening

Apparently low maternal serum inhibin A levels in second-trimester screening

2005 ◽  
Vol 25 (10) ◽  
pp. 967-968 ◽  
Author(s):  
Geralyn M. Lambert-Messerlian ◽  
David F. Keren ◽  
Constantine S. Raphtis ◽  
Krista Byberg ◽  
Jacob A. Canick
Keyword(s):  
Maternal Serum ◽  
Second Trimester ◽  
Inhibin A ◽  
Second Trimester Screening ◽  
Trimester Screening

Is MSAFP Still a Useful Test for Detecting Open Neural Tube Defects and Ventral Wall Defects in the Era of First-Trimester and Early Second-Trimester Fetal Anatomical Ultrasounds?

2014 ◽  
Vol 37 (3) ◽  
pp. 206-210 ◽  
Author(s):  
Ashley S. Roman ◽  
Simi Gupta ◽  
Nathan S. Fox ◽  
Daniel Saltzman ◽  
Chad K. Klauser ◽  
...  
Keyword(s):  
Neural Tube ◽  
Neural Tube Defects ◽  
Gestational Age ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Maternal Serum ◽  
Fisher Exact Test ◽  
Ultrasound Screening ◽  
Second Trimester ◽  
Ventral Wall

Introduction: To evaluate whether maternal serum α-fetoprotein (MSAFP) improves the detection rate for open neural tube defects (ONTDs) and ventral wall defects (VWD) in patients undergoing first-trimester and early second-trimester fetal anatomical survey. Material and Methods: A cohort of women undergoing screening between 2005 and 2012 was identified. All patients were offered an ultrasound at between 11 weeks and 13 weeks and 6 days of gestational age for nuchal translucency/fetal anatomy followed by an early second-trimester ultrasound at between 15 weeks and 17 weeks and 6 days of gestational age for fetal anatomy and MSAFP screening. All cases of ONTD and VWD were identified via query of billing and reporting software. Sensitivity and specificity for detection of ONTD/VWD were calculated, and groups were compared using the Fisher exact test, with p < 0.05 as significance. Results: A total of 23,790 women met the criteria for inclusion. Overall, 15 cases of ONTD and 17 cases of VWD were identified; 100% of cases were diagnosed by ultrasound prior to 18 weeks' gestation; none were diagnosed via MSAFP screening (p < 0.001). First-trimester and early second-trimester ultrasound had 100% sensitivity and 100% specificity for diagnosing ONTD/VWD. Discussion: Ultrasound for fetal anatomy during the first and early second trimester detected 100% of ONTD/VWD in our population. MSAFP is not useful as a screening tool for ONTD and VWD in the setting of this ultrasound screening protocol.

Extreme Values of Maternal Serum Analytes in Second Trimester Screening: Looking Beyond Trisomy and NTD’s

2011 ◽  
Vol 20 (4) ◽  
pp. 396-403 ◽  
Author(s):  
Elizabeth McPherson ◽  
Ginger D. Thomas ◽  
Christopher Manlick ◽  
Christina A. Zaleski ◽  
Kara K. Reynolds ◽  
...  
Keyword(s):  
Extreme Values ◽  
Maternal Serum ◽  
Second Trimester ◽  
Second Trimester Screening ◽  
Trimester Screening
Sign in / Sign up

Export Citation Format

Share Document